Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abaloparatide + Bevacizumab in MDS
NCT03746041Phase 1Completed
- Sponsor
- University of Rochester
- Start
- Feb 2019
- Primary completion
- Apr 2022
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abaloparatide and bevacizumab in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by University of Rochester. Primary endpoint: Therapy-limiting Toxicity at 7 months. Started Feb 2019; status: completed.
02
Drugs
abaloparatidebevacizumab
03
Conditions
myelodysplastic syndromes (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03746041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746041.